Suppr超能文献

加强流行病学观察性研究报告的规范(STROBE):HE4 和 CA125 是否适合检测外阴 Pagets 病?

A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?

机构信息

Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari.

Department of Obstetrics and Gynecology, "Valle d'Itria" Hospital, Martina Franca, Taranto.

出版信息

Medicine (Baltimore). 2021 Feb 5;100(5):e24485. doi: 10.1097/MD.0000000000024485.

Abstract

Paget disease is a complex disorder that can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget's disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the main objective of this study is to evaluate if the human epididymis protein 4 (HE4) and cancer antigen125 (CA125) can promote recognition of PVD in early stages and during the relapses.we have conducted a prospective, observational and laboratory-based study, that included 50 patients, whose 25 healthy women represented the control group and 25 PVD patients, which have been operated in our Oncology Institute, from May 2017 to September 2019. Both in the control group and in PVD patients, the CA-125 and HE4 were evaluated before surgery and after 6 months. Finally, a comparison of markers serum level, both between before/after surgery and with control group, and a ROC (Receiver Operating Characteristic) curve were performed.Dosing the markers in PVD patients, 3/25 (12%) showed a higher value of CA125 and 11/25 (44%) an increased HE4. In addition, after surgical treatment there were no statistically significant difference between levels of CA-125 (P = .3) and HE4 (P = .19). On the other hand, comparing HE4 in PVD patients with the control group, a statistically significant difference was found (P-value = .0036). Contrary, comparing CA-125 in PVD patients with the control group (P-value= .1969), no statistically significant difference was evidenced. Moreover, ROC (Receiver Operating Characteristic) curve showed low sensitivity and specificity for CA125 with area under curve (AUC) = 0.5608. Instead, the ROC curve of HE4 revealed a sensitivity and specificity of 76% and 88% respectively (AUC = 0.7408) using a cut-off at 90 pmol/L.Despite the limited cases, our data showed that CA125 is not a sensitive marker for PVD. On the other hand, in 44% of PVD we've seen an increase in HE4. So, this could be a starting point for further research that could confirm the possibility to use this marker in order to support PVD early identification.

摘要

佩吉特病是一种复杂的疾病,可以在乳房(乳腺佩吉特病)或其他部位(乳腺外佩吉特病)中识别,如肛门生殖器皮肤(外阴佩吉特病-PVD)。这种疾病的死亡率较低,但晚期诊断和复发会对预后产生负面影响。因此,本研究的主要目的是评估人附睾蛋白 4(HE4)和癌抗原 125(CA125)是否可以促进对 PVD 的早期识别和复发。

我们进行了一项前瞻性、观察性和基于实验室的研究,纳入了 50 名患者,其中 25 名健康女性为对照组,25 名 PVD 患者在我们的肿瘤研究所接受了手术,时间为 2017 年 5 月至 2019 年 9 月。在对照组和 PVD 患者中,在手术前和手术后 6 个月评估 CA-125 和 HE4。最后,对标记物血清水平进行了比较,包括手术前后与对照组之间的比较,并进行了 ROC(接收者操作特征)曲线分析。

在 PVD 患者中测定标志物,25 例中有 3 例(12%)CA125 值升高,11 例(44%)HE4 升高。此外,手术后 CA-125 水平(P=0.3)和 HE4(P=0.19)无统计学差异。另一方面,与对照组相比,PVD 患者的 HE4 有统计学差异(P 值=0.0036)。相反,与对照组相比,PVD 患者的 CA-125(P 值=0.1969)无统计学差异。此外,ROC(接收者操作特征)曲线显示 CA125 的灵敏度和特异性较低,曲线下面积(AUC)为 0.5608。相反,HE4 的 ROC 曲线显示灵敏度和特异性分别为 76%和 88%(AUC=0.7408),使用 90pmol/L 作为截断值。

尽管病例有限,但我们的数据表明 CA125 不是 PVD 的敏感标志物。另一方面,我们发现 44%的 PVD 患者 HE4 升高。因此,这可能是进一步研究的起点,可以证实使用这种标志物来支持 PVD 的早期识别的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab42/7870238/708a71066101/medi-100-e24485-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验